Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates
XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-op...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1264456/full |
| _version_ | 1797661839025242112 |
|---|---|
| author | William Rhys-Williams Helen Marie Galvin William Guy Love |
| author_facet | William Rhys-Williams Helen Marie Galvin William Guy Love |
| author_sort | William Rhys-Williams |
| collection | DOAJ |
| description | XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative Staphylococcus species from 33 countries. XF-73 was found to be effective against all isolates tested, with MICs ranging between ≤0.12 – 4 µg/ml (MIC50 and MIC90 values of 0.5 and 1 µg/ml respectively). XF-73 was found to be equally effective against antibiotic resistant isolates as antibiotic sensitive isolates, with no impact of pre-existing antibiotic resistance mechanisms to cell wall synthesis inhibitors (β-lactams, carbapenems, glycopeptides and cephalosporins), protein synthesis inhibitors (oxazolidinones, macrolides and tetracyclines), DNA synthesis inhibitors (fluoroquinolones) and a folate synthesis inhibitor. The panel selected also included examples of multidrug-resistant S. aureus isolates and, in all cases, the XF-73 MIC ranges were found to be similar against each of these groups. This dataset expands the knowledge of the breadth of activity of this novel antibacterial against a wide range of global S. aureus isolates and supports the potential utility of XF-73 for the treatment of patients who are S. aureus nasal carriers. Similar results were also obtained for multidrug-resistant isolates of other Staphylococcus species included in the study and collectively support the continued clinical development of XF-73 as an effective anti-staphylococcal drug. |
| first_indexed | 2024-03-11T18:51:31Z |
| format | Article |
| id | doaj.art-4101f55877c64cf8915a9c7e0940a616 |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-03-11T18:51:31Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-4101f55877c64cf8915a9c7e0940a6162023-10-11T09:38:13ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882023-10-011310.3389/fcimb.2023.12644561264456Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolatesWilliam Rhys-WilliamsHelen Marie GalvinWilliam Guy LoveXF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of Staphylococcus aureus in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative Staphylococcus species from 33 countries. XF-73 was found to be effective against all isolates tested, with MICs ranging between ≤0.12 – 4 µg/ml (MIC50 and MIC90 values of 0.5 and 1 µg/ml respectively). XF-73 was found to be equally effective against antibiotic resistant isolates as antibiotic sensitive isolates, with no impact of pre-existing antibiotic resistance mechanisms to cell wall synthesis inhibitors (β-lactams, carbapenems, glycopeptides and cephalosporins), protein synthesis inhibitors (oxazolidinones, macrolides and tetracyclines), DNA synthesis inhibitors (fluoroquinolones) and a folate synthesis inhibitor. The panel selected also included examples of multidrug-resistant S. aureus isolates and, in all cases, the XF-73 MIC ranges were found to be similar against each of these groups. This dataset expands the knowledge of the breadth of activity of this novel antibacterial against a wide range of global S. aureus isolates and supports the potential utility of XF-73 for the treatment of patients who are S. aureus nasal carriers. Similar results were also obtained for multidrug-resistant isolates of other Staphylococcus species included in the study and collectively support the continued clinical development of XF-73 as an effective anti-staphylococcal drug.https://www.frontiersin.org/articles/10.3389/fcimb.2023.1264456/fullexeporfinium chlorideXF-73Staphylococcus aureusMRSAStaphylococcus speciesMIC |
| spellingShingle | William Rhys-Williams Helen Marie Galvin William Guy Love Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates Frontiers in Cellular and Infection Microbiology exeporfinium chloride XF-73 Staphylococcus aureus MRSA Staphylococcus species MIC |
| title | Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates |
| title_full | Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates |
| title_fullStr | Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates |
| title_full_unstemmed | Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates |
| title_short | Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates |
| title_sort | screening of the novel antimicrobial drug xf 73 against 2 527 staphylococcus species clinical isolates |
| topic | exeporfinium chloride XF-73 Staphylococcus aureus MRSA Staphylococcus species MIC |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1264456/full |
| work_keys_str_mv | AT williamrhyswilliams screeningofthenovelantimicrobialdrugxf73against2527staphylococcusspeciesclinicalisolates AT helenmariegalvin screeningofthenovelantimicrobialdrugxf73against2527staphylococcusspeciesclinicalisolates AT williamguylove screeningofthenovelantimicrobialdrugxf73against2527staphylococcusspeciesclinicalisolates |